Pharmacogenetics of coumarin anticoagulants in Brazilians

Bibliography

• Suarez-Kurtz G, Pena SD. Pharmacogenomics in the Americas: the impact of genetic admixture. Curr Drug Targets 2006;7:1649-58
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Paula DP, Struchiner CJ. Pharmacogenomic implications of population admixture: brazil as a model case. Pharmacogenomics 2014;15:209-19
   PubMed Web of Science ®Google Scholar
• Instituto Brasileiro de Geografia e Estatística. 2014. Available from: http://www.ibge.gov.br [Last accessed 10 July 2014]
   Google Scholar
• Pena SD, Di Pietro G, Fuchshuber-Moraes M, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 2011;6:e17063
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Pena SD, Struchiner CJ, et al. Pharmacogenomic diversity among Brazilians: influence of ancestry, self-reported color, and geographical origin. Front Pharmacol 2012;3:191
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G. Pharmacogenetics in the Brazilian population. Front Pharmacogenet 2010;1:1-10
   PubMed Web of Science ®Google Scholar
• Agência Nacional de Vigilância Sanitária. Available from: http://www.anvisa.gov.br [Last accessed 11 July 2014]
   Google Scholar
• Perini JA, Struchiner CJ, Silva-Assuncao E, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian Patients. Clin Pharmacol Ther 2008;84:722-8
   PubMed Web of Science ®Google Scholar
• Lima MV, Ribeiro GS, Mesquita ET, et al. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 2008;64:9-15
   PubMed Web of Science ®Google Scholar
• Orsi FA, Annichino Bizzacchi JM, de Paula EV, et al. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res 2010;126:e206-10
   PubMed Web of Science ®Google Scholar
• Botton MR, Bandinelli E, Rohde LE, et al. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011;72:442-50
   PubMed Web of Science ®Google Scholar
• Santos PC, Dinardo CL, Schettert IT, et al. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol 2013;69:789-97
   PubMed Web of Science ®Google Scholar
• Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433
   PubMed Web of Science ®Google Scholar
• McDonald MG, Rieder MJ, Nakano M, et al. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 2009;75:1337-46
   PubMed Web of Science ®Google Scholar
• Perini JA, Struchiner CJ, Silva-Assuncao E, et al. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010;87:417-20
   PubMed Web of Science ®Google Scholar
• Nebert DW. Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. Eur J Pharmacol 2000;410:107-20
   PubMed Web of Science ®Google Scholar
• Danese E, Montagnana M, Johnson JA, et al. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. Clin Pharmacol Ther 2012;92:746-56
   PubMed Web of Science ®Google Scholar
• Fuchshuber-Moraes M, Perini JA, Rosskopf D, et al. Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. Eur J Clin Pharmacol 2009;65:789-93
   PubMed Web of Science ®Google Scholar
• van ’t Hooft FM, Silveira A, Tornvall P, et al. Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 1999;93:3432-41
   PubMed Web of Science ®Google Scholar
• Shikata E, Ieiri I, Ishiguro S, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004;103:2630-5
   PubMed Web of Science ®Google Scholar
• D’Ambrosio RL, D’Andrea G, Cappucci F, et al. Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 2004;89:1510-16
   PubMed Web of Science ®Google Scholar
• De Oliveira Almeida VC, De Souza Ferreira AC, Ribeiro DD, et al. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J Thromb Haemost 2011;9:2120-2
   PubMed Web of Science ®Google Scholar
• Estrela RC, Ribeiro FS, Carvalho RS, et al. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics 2008;9:267-76
   PubMed Web of Science ®Google Scholar
• Sortica Vde A, Ojopi EB, Genro JP, et al. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol 2012;110:460-8
   PubMed Web of Science ®Google Scholar
• Wadelius M, Sörlin K, Wallerman O, et al. Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004;4:40-8
   PubMed Web of Science ®Google Scholar
• Botton MR, Viola PP, Bandinelli E, et al. A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. Basic Clin Pharmacol Toxicol 2014;114:323-9
   PubMed Web of Science ®Google Scholar
• Limdi N, Goldstein J, Blaisdell J, et al. Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med 2007;4:157-69
   PubMed Web of Science ®Google Scholar
• Zuchinali P, Souza GC, Aliti G, et al. Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients. J Thromb Thrombolysis 2014;37:338-44
   PubMed Web of Science ®Google Scholar
• Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010;115:3827-34
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G, Perini JA, Silva-Assunção E, et al. Relative contribution of VKORC1, CYP2C9, and INR response to warfarin stable dose. Blood 2009;113:4125-6
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G. Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 2011;72:451-3
   PubMed Web of Science ®Google Scholar
• Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-31
   PubMed Web of Science ®Google Scholar
• Klein TE, Altman RB, Eriksson N, et al. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N Engl J Med 2009;360:753-64
   PubMed Web of Science ®Google Scholar
• Shin J, Cao D. Comparison of warfarin pharmacogenetic dosing algorithms in a racially diverse large cohort. Pharmacogenomics 2011;12:125-34
   PubMed Web of Science ®Google Scholar
• Tan GM, Wu E, Lam YY, et al. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010;11:439-48
   PubMed Web of Science ®Google Scholar
• Puehringer H, Loreth RM, Klose G, et al. VKORC1 −1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement. Eur J Clin Pharmacol 2010;66:591-8
   PubMed Web of Science ®Google Scholar
• van Schie RM, Wessels JA, le Cessie S, et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011;32:1909-17
   PubMed Web of Science ®Google Scholar
• Teichert M, Eijgelsheim M, Uitterlinden AG, et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet Genomics 2011;21:26-34
   PubMed Web of Science ®Google Scholar
• van Schie RM, Aoussar A, van der Meer FJ, et al. Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses. J Thromb Haemost 2013;11:1200-3
   PubMed Web of Science ®Google Scholar
• Werner D, Werner U, Wuerfel A, et al. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol 2009;65:783-8
   PubMed Web of Science ®Google Scholar
• Suarez-Kurtz G. Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network – REFARGEN. Pharmacogenomics J 2004;4:347-8
   PubMed Web of Science ®Google Scholar
• Rede Nacional de Farmacogenética - REFARGEN. Available from: http://www.refargen.org.br [Last accessed 11 July 2014]
   Google Scholar
• Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112:1022-7
   PubMed Web of Science ®Google Scholar
• Cha PC, Mushiroda T, Takahashi A, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010;19:4735-44
   PubMed Web of Science ®Google Scholar
• Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet 2013;382:790-6
   PubMed Web of Science ®Google Scholar
• Verhoef TI, Ragia G, de Boer A, et al. A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013;369:2304-12
   PubMed Web of Science ®Google Scholar
• Kimmel SE, French B, Kasner SE, et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013;369:2283-93
   PubMed Web of Science ®Google Scholar
• Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-303
   PubMed Web of Science ®Google Scholar
• Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med 2013;369:2345-6
   PubMed Web of Science ®Google Scholar
• Cavallari LH, Kittles RA, Perera MA. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1763
   PubMed Web of Science ®Google Scholar
• Daneshjou R, Klein TE, Altman RB. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1762-3
   PubMedGoogle Scholar
• Kimmel SE, French B, Geller NL, Investigators C. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1763-4
   PubMed Web of Science ®Google Scholar
• Koller EA, Roche JC, Rollins JA. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1761
   PubMedGoogle Scholar
• Maitland-van der Zee AH, de Boer A, Manolopoulos VG, Group E-P. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1765-6
   PubMed Web of Science ®Google Scholar
• Pereira NL, Rihal CS, Weinshilboum RM. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1762
   PubMedGoogle Scholar
• Pirmohamed M, Wadelius M, Kamali F, Group E-P. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1764-5
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Kim RB, Tirona RG. Genotype-guided dosing of vitamin K antagonists. N Engl J Med 2014;370:1761-2
   PubMedGoogle Scholar